104060-25-5Relevant academic research and scientific papers
NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF
-
Paragraph 1869; 1870, (2016/07/05)
There is provided a morpholine derivative represented by General Formula [1A] or a salt thereof. (In the formula, a ring A represents a ring represented by General Formula [I]; * represents a bonding position; Z2 represents CH or the like; Z1 represents CR6 or the like; R6 represents a hydrogen atom or the like; X1 represents CHR7 or the like; R7 represents a hydrogen atom or the like; X2 represents CH2 or the like; R1 and R2 are the same as or different from each other, and each of R1 and R2 represents a hydrogen atom or the like; R3, R4, and R5 are the same as or different from each other, and each of R3, R4, and R5 represents a hydrogen atom, NRaRb, or the like; and each of Ra and Rb represents a hydrogen atom, a C1-8 alkyl group which may have a substituent, or the like.)
Discovery and pharmacological profile of new 1H-indazole-3-carboxamide and 2H-pyrrolo[3,4-c]quinoline derivatives as selective serotonin 4 receptor ligands
Furlotti, Guido,Alisi, Maria Alessandra,Apicella, Claudia,Capezzone De Joannon, Alessandra,Cazzolla, Nicola,Costi, Roberta,Cuzzucoli Crucitti, Giuliana,Garrone, Beatrice,Iacovo, Alberto,Magarò, Gabriele,Mangano, Giorgina,Miele, Gaetano,Ombrato, Rosella,Pescatori, Luca,Polenzani, Lorenzo,Rosi, Federica,Vitiello, Marco,Di Santo, Roberto
, p. 9446 - 9466 (2013/01/16)
Since the discovery of the serotonin 4 receptor (5-HT4R), a large number of receptor ligands have been studied. The safety concerns and the lack of market success of these ligands have mainly been attributed to their lack of selectivity. In thi
COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT
-
Page/Page column 37, (2010/04/03)
Compound of formula (I) in which R1, R2 and R3 are defined in the following description, and the pharmaceutically acceptable acid-addition or base-addition salts thereof. The invention also relates to a process and an intermediate for preparing it, and to a pharmaceutical composition comprising it. The invention also relates to the use of a novel 2H-pyrrolo[3,4-c]quinoline compound for preparing a pharmaceutical composition that is active in the treatment of disturbances of the serotoninergic system.
